secwatch.observer — SEC 8-K summary
======================================

Issuer:     OptiNose, Inc. (—)
CIK:        0001494650
Form:       8-K
Filed at:   2024-03-14T23:59:59+00:00
Accession:  0001494650-24-000029
Event type: regulatory
Sentiment:  positive
Materiality: 0.55
Item codes: 1.01, 8.01
LLM model:  deepseek-v4-flash:cloud@v2

OptiNose gets FDA nod for Hikma as second XHANCE manufacturing site; signs supply deal
--------------------------------------------------------------------------------

- FDA approved Hikma as an additional manufacturing site for finished XHANCE units on March 9, 2024.
- OptiNose entered a Manufacturing and Supply Agreement with Hikma with binding forecast and minimum purchase obligations.
- Agreement runs through December 31, 2026, with termination rights for material breach or IP claims.
- Two approved sites now: Hikma and Contract Pharmaceuticals Limited Canada.
- Annual minimum purchase requirement included; failure triggers a specified fee payment.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1494650/000149465024000029/0001494650-24-000029-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1494650/000149465024000029/optn-20240309.htm
  HTML page:      https://secwatch.observer/filing/0001494650-24-000029

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer